Physician profile
Saurabh Sethi
NPI 1215165600
$69,388.46
in general payments reported to CMS, 2019-2025
26 companies · $60K in 2025
The $60K reported for 2025 was more than what 98% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $554 · 2020: $163 · 2021: $321 · 2022: $3,369 · 2023: $2,023 · 2024: $2,580 · 2025: $60K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $42K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $21K · Food and Beverage: $2,596 · Education: $109.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $41,500.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $20,775.00 |
| Food and Beverage | $2,596.28 |
| Education | $109.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $41,596.71 | 2021-2025 | Xifaxan, Trulance |
| Exact Sciences Corporation | $18,000.00 | 2025 | Cologuard Collection Kit |
| Abbvie INC. | $6,486.86 | 2020-2025 | Creon, Linzess, Viberzi |
| Janssen Biotech, INC. | $800.76 | 2022-2025 | Stelara, Tremfya |
| Gilead Sciences, INC. | $541.12 | 2019-2025 | |
| Ironwood Pharmaceuticals, INC | $275.26 | 2022-2024 | Linzess |
| Qol Medical, LLC | $211.32 | 2023-2025 | Sucraid, Sucraid |
| Redhill Biopharma INC. | $175.98 | 2021-2023 | Aemcolo, Talicia, Movantik |
| Madrigal Pharmaceuticals | $137.94 | 2024-2025 | Rezdiffra, Resmetirom |
| Takeda Pharmaceuticals U.S.A., INC. | $123.61 | 2021 | |
| Boston Scientific Corporation | $117.76 | 2019 | |
| Merck Sharp & Dohme LLC | $109.51 | 2022-2023 | Dificid |
| Aimmune Therapeutics, INC. | $109.29 | 2025 | Zenpep |
| Vifor Pharma, INC. | $89.50 | 2019 | |
| Celltrion USA INC. | $88.33 | 2023-2025 | Vegzelma, Yuflyma |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Braintree Laboratories, INC. | $73.50 | 2024-2025 | Sutab, Suflave |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $67.20 | 2019 | |
| Phathom Pharmaceuticals, INC. | $61.93 | 2024-2025 | Voquezna |
| Boehringer Ingelheim Pharmaceuticals, INC. | $56.45 | 2023 | Cyltezo |
| Intercept Pharmaceuticals, INC. | $55.49 | 2023 | Ocaliva |
| Pentax of America, INC. | $54.97 | 2024 | Pentax Medical, C2 Cryoballoon, C2 Cryoballoon Focal Controller |
| Fresenius Kabi USA, LLC | $51.32 | 2023-2024 | Idacio |
| Ardelyx, INC. | $31.89 | 2025 | Ibsrela |
| Echosens North America, INC. | $28.27 | 2025 | Fibroscan |
| Novo Nordisk INC | $24.19 | 2025 | Wegovy |
| Daiichi Sankyo INC. | $19.30 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Saurabh Sethi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.